Current Heart Failure Reports最新文献_第3页

Advances in Living Myocardial Slice Technology for Heart Failure Research. 活体心肌切片技术在心力衰竭研究中的进展

IF 3.7

Current Heart Failure Reports Pub Date : 2026-05-13 DOI: 10.1007/s11897-026-00762-z

Azra Husetić, Anke M Smits, Monika M Gladka

{"title":"Advances in Living Myocardial Slice Technology for Heart Failure Research.","authors":"Azra Husetić, Anke M Smits, Monika M Gladka","doi":"10.1007/s11897-026-00762-z","DOIUrl":"10.1007/s11897-026-00762-z","url":null,"abstract":"Purpose: The development of effective treatments for heart failure (HF) often fails due to the lack of preclinical models that closely reflect the native structure and function of the human myocardium. Living myocardial slices (LMS) are ultra-thin sections of heart tissue that have shown to retain the complexity, multicellularity, and function of the innate adult myocardium. The number of studies using LMS for HF research and its underlying diseases has been increasing rapidly over the last few years, mainly due to methodological advances that have prolonged LMS culture. This review summarizes key findings and various applications of LMS in HF research.Recent findings: LMS derived from both animal and human hearts, including end-stage HF explants, donor hearts, or surgical specimens, have increasingly been used to model HF and related cardiac diseases. Moreover, LMS have enabled the study of human-specific responses to potential therapeutic drugs and replicate other drug-related effects, such as cardiotoxicity, as they appear in the clinic. Additionally, they have been used to validate the impact of gene delivery of pro-regenerative targets previously investigated in animal studies. More recently, LMS platforms have also been used to mimic device therapy for HF patients by controlling the mechanical and electrical parameters of LMS in culture. LMS represent a physiologically relevant model that bridges the gap between conventional in vitro systems and in vivo models in HF research. Despite remaining challenges related to tissue availability and culturing, LMS provide a highly translational platform for testing potential treatment strategies and understanding the underlying mechanisms of HF.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13171700/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147927308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Sex Differences in LVAD Therapy: From Diagnosis to Destination. LVAD治疗的性别差异：从诊断到目的地。

IF 3.7

Current Heart Failure Reports Pub Date : 2026-05-09 DOI: 10.1007/s11897-026-00756-x

Jarrett Fowler, Mahwash Kassi

{"title":"Sex Differences in LVAD Therapy: From Diagnosis to Destination.","authors":"Jarrett Fowler, Mahwash Kassi","doi":"10.1007/s11897-026-00756-x","DOIUrl":"10.1007/s11897-026-00756-x","url":null,"abstract":"Purpose: Sex disparities in left ventricular assist device (LVAD) therapy remain a significant challenge in advanced heart failure care. This review synthesizes evidence on differences in epidemiology, clinical presentation, anatomical suitability, complications, and long-term recovery to clarify why women remain underrepresented despite comparable survival with contemporary devices.Recent findings: Women constitute nearly half of the heart failure population but only 20-25% of LVAD implantations. They often present later with HF phenotypes marked by microvascular dysfunction, diastolic stiffness, smaller ventricular size, and reduced right-sided reserve, increasing perceived procedural risk. Although contemporary centrifugal-flow devices have eliminated sex-based survival differences, women experience higher rates of hemorrhagic stroke, pump thrombosis, rehospitalization, and psychosocial burden. Contributing factors include device-patient mismatch, differences in clinical presentation, and disparities in referral and timing of evaluation for advanced heart failure therapies. Emerging innovations, such as miniaturized pumps, sex-specific risk models, and improved hemodynamic assessment, aim to reduce these disparities. Achieving equity will require adaptable device designs, sex-specific diagnostic thresholds, individualized perioperative management, and greater female representation in clinical research.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Face-to-Face and Internet-based Cognitive Behavioral Therapy for Patients with Heart Failure: an Umbrella Review of Systematic Reviews and Meta-analyses. 心衰患者的面对面和基于互联网的认知行为治疗：系统评价和荟萃分析的综合综述。

IF 3.7

Current Heart Failure Reports Pub Date : 2026-05-09 DOI: 10.1007/s11897-026-00760-1

Huinan Liu, Zhixiang Peng, Wai Kai Hou

{"title":"Face-to-Face and Internet-based Cognitive Behavioral Therapy for Patients with Heart Failure: an Umbrella Review of Systematic Reviews and Meta-analyses.","authors":"Huinan Liu, Zhixiang Peng, Wai Kai Hou","doi":"10.1007/s11897-026-00760-1","DOIUrl":"10.1007/s11897-026-00760-1","url":null,"abstract":"Purpose of review: The present study aims to provide an up-to-date umbrella review of existing meta-analyses of randomized control trials (RCT) of cognitive behavioral therapy (CBT) among patients with heart failure (HF).Recent findings: The umbrella review covered five meta-analyses published in the past five years with 18 primary studies (conducted between 2010 and 2022) of 1,687 non-duplicated patients aged 51.63 to 77.40. Primary studies originated from the USA, Sweden, Netherlands, China, Iran, and Philippines. Common benefits of CBT included depressive symptoms (89%), quality of life (56%), anxiety symptoms (39%), self-care (33%), 6-minute walk distance (33%), and health status (17%). Evidence varied depending on the timepoint of follow-up assessment and the specific measurement used to evaluate the outcome. No meta-analyses pooled the effect sizes for iCBT and analyzed the specific therapeutic elements in CBT. No meta-regression was performed. Individual participant data meta-analyses with meta-regression should be performed to identify common moderators and factors that can influence treatment adherence. The current research would also benefit from additional RCT evidence focusing specifically on iCBT for patients with HF.","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-05-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13157393/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147863843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Dynamic Nature of Caregiving in Advanced Heart Failure With Left Ventricular Assist Device Support: A Systematic Review and Thematic Synthesis. 在左心室辅助装置支持下晚期心力衰竭患者护理的动态性质：系统回顾和专题综合。

IF 3.7

Current Heart Failure Reports Pub Date : 2026-04-30 DOI: 10.1007/s11897-026-00758-9

Magda Eriksson-Liebon, Naoko P Kato, Binyamin Ben Avraham, Tuvia Ben Gal, Tiny Jaarsma, Anna Strömberg, Maria Liljeroos

{"title":"The Dynamic Nature of Caregiving in Advanced Heart Failure With Left Ventricular Assist Device Support: A Systematic Review and Thematic Synthesis.","authors":"Magda Eriksson-Liebon, Naoko P Kato, Binyamin Ben Avraham, Tuvia Ben Gal, Tiny Jaarsma, Anna Strömberg, Maria Liljeroos","doi":"10.1007/s11897-026-00758-9","DOIUrl":"10.1007/s11897-026-00758-9","url":null,"abstract":"PURPOSE OF REVIEW: Advanced heart failure is a growing global health challenge, and the use of Left Ventricular Assist Devices (LVADs) as a long-term treatment has increased. This development shifts substantial responsibility to informal caregivers, who play a crucial role in patients’ daily management and wellbeing. However, knowledge about caregivers’ experiences across the entire LVAD trajectory remains limited. This review aims to synthesize available evidence on informal caregivers’ experiences of everyday life when supporting an adult patient with advanced heart failure treated with an LVAD. RECENT FINDINGS: This systematic review and thematic synthesis included 17 studies. The analysis identified ten descriptive themes related to caregivers’ experiences, which were further synthesized into four analytical themes: Before LVAD implantation, Early post-LVAD, Later post-LVAD, and End of the LVAD journey. These themes illustrate the evolving and dynamic nature of caregiving across the LVAD trajectory. In addition, one overarching analytical theme, The caregiver’s network of support, was identified. The findings highlight caregivers’ experiences of both receiving and providing support through formal and informal networks throughout the LVAD trajectory, emerging as a continuous and integral component of caregiving. The review underscores the importance of sustained and structured support for caregivers across the entire LVAD pathway, rather than support limited to specific time points. ","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13132901/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764880","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Human Leukocyte Antigen Determinants in Myocarditis and Dilated Cardiomyopathy. 人白细胞抗原决定因素在心肌炎和扩张型心肌病。

IF 3.7

Current Heart Failure Reports Pub Date : 2026-04-24 DOI: 10.1007/s11897-026-00761-0

Nihit Goli, Jennifer Wilcox, John Barnard, W H Wilson Tang

{"title":"Human Leukocyte Antigen Determinants in Myocarditis and Dilated Cardiomyopathy.","authors":"Nihit Goli, Jennifer Wilcox, John Barnard, W H Wilson Tang","doi":"10.1007/s11897-026-00761-0","DOIUrl":"10.1007/s11897-026-00761-0","url":null,"abstract":"PURPOSE OF REVIEW: Myocarditis, defined as inflammation of heart muscle, can be triggered by viral infection or have an autoimmune origin. In some cases, it progresses to dilated cardiomyopathy (DCM) and heart failure. The human leukocyte antigen (HLA) system is important in adaptive immunity by influencing antigen presentation and autoimmunity. This review intends to clarify the role of HLA polymorphisms in the progression, resistance, and outcomes of myocarditis and DCM. RECENT FINDINGS: Evidence indicates that HLA is linked to myocarditis and DCM through familial aggregation, myocardial HLA upregulation, circulating cardiac autoantibodies, candidate association studies, genome-wide association signals at chromosome 6p21, and transgenic models demonstrating HLA-restricted disease susceptibility. HLA alleles influence viral clearance, molecular mimicry, autoimmune priming, cytokine signaling, and pathogen-specific autoantibody production. Translation of this evidence into clinical practice has been limited by modest effect sizes, population variability, and the lack of genotype-guided therapies. Using HLA as a risk-stratification tool can allow more accurate surveillance and immunomodulatory strategies for myocarditis and DCM. Future research priorities should include multi-ethnic HLA studies, viral epitope mapping, integration of immune profiling, and HLA-stratified clinical trials. ","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13109210/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764888","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IGFBP7 and Heart Failure: From Senescence Biomarker to Therapeutic Target. IGFBP7与心力衰竭：从衰老生物标志物到治疗靶点。

IF 3.7

Current Heart Failure Reports Pub Date : 2026-04-21 DOI: 10.1007/s11897-026-00750-3

Maissa El-Qendouci, Raluca Chelu, Mahmoud Abdellatif, Pardeep Jhund, Rudolf A de Boer, Navin Suthahar

{"title":"IGFBP7 and Heart Failure: From Senescence Biomarker to Therapeutic Target.","authors":"Maissa El-Qendouci, Raluca Chelu, Mahmoud Abdellatif, Pardeep Jhund, Rudolf A de Boer, Navin Suthahar","doi":"10.1007/s11897-026-00750-3","DOIUrl":"10.1007/s11897-026-00750-3","url":null,"abstract":"PURPOSE OF REVIEW: To integrate clinical and preclinical evidence on insulin-like growth factor-binding protein-7 (IGFBP7) in heart failure (HF) and identify key priorities for advancing IGFBP7-targeted therapies toward human translation. RECENT FINDINGS: Circulating IGFBP7 is strongly associated with HF development, diastolic dysfunction, and disease progression across HF phenotypes. Preclinical studies show that genetic or pharmacologic inhibition of IGFBP7 attenuates cardiac remodelling, reduces cardiomyocyte senescence, and ameliorates cardiac dysfunction in murine HF models. Apparent mechanistic discrepancies between studies likely reflect cell-specific actions: cardiomyocyte-derived IGFBP7 activates IGF-1 receptor signalling, promoting cardiomyocyte hypertrophy and senescence, whereas endothelial-derived IGFBP7 inhibits cardiomyocyte insulin receptor signalling, impairing metabolic homeostasis. IGFBP7 is a senescence-associated biomarker linked to HF development, diastolic dysfunction, and HF progression. Preclinical studies converge on the conclusion that IGFBP7 inhibition attenuates cardiac remodelling and ameliorates cardiac dysfunction in experimental HF, positioning IGFBP7 as a promising therapeutic target. Ongoing research into IGFBP7-targeted strategies may expand HF treatment beyond conventional hemodynamic and neurohormonal interventions by directly addressing the biology of cardiovascular ageing and senescence-driven myocardial dysfunction. ","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-04-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13099848/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147764952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction to: Changes in Physical Activity Following Heart Failure in Humans and Animal Models: A Scoping Review. 修正：人类和动物模型心力衰竭后体力活动的变化：一项范围综述。

IF 3.4

Current Heart Failure Reports Pub Date : 2026-04-18 DOI: 10.1007/s11897-026-00759-8

Akinori Kaneguchi, Mahiro Fukunaga, Takuya Umehara

引用次数: 0

Understanding Geographic Variations in Heart Failure Clinical Trials. 了解心力衰竭临床试验的地理差异。

IF 3.7

Current Heart Failure Reports Pub Date : 2026-04-17 DOI: 10.1007/s11897-026-00753-0

Luca Fazzini, Giada Colombo, Gregorio Tersalvi, Jolie Bruno, Riccardo M Inciardi, Emilia D'Elia

引用次数: 0

TIM-3 in Cardiovascular Disease. TIM-3在心血管疾病中的作用。

IF 3.7

Current Heart Failure Reports Pub Date : 2026-04-07 DOI: 10.1007/s11897-026-00755-y

Laura I Yousif, Aukje G Sijtema, Margot J Chevalier, Rudolf A de Boer, Wouter C Meijers

引用次数: 0

Implementation of Machine Learning in Heart Failure Trials. 机器学习在心力衰竭试验中的应用。

IF 3.7

Current Heart Failure Reports Pub Date : 2026-03-28 DOI: 10.1007/s11897-026-00752-1

Letizia Rosa Romano, Marta Scimeca Odorico, Antonio Curcio

{"title":"Implementation of Machine Learning in Heart Failure Trials.","authors":"Letizia Rosa Romano, Marta Scimeca Odorico, Antonio Curcio","doi":"10.1007/s11897-026-00752-1","DOIUrl":"10.1007/s11897-026-00752-1","url":null,"abstract":"PURPOSE OF REVIEW: Heart failure (HF) is a heterogeneous syndrome that challenges the design and interpretation of results from clinical trials. This review examines how machine learning (ML) can address methodological constraints of traditional trial models, such as rigid eligibility criteria, fixed endpoints, and limited external validity. RECENT FINDINGS: By integrating multimodal data from electronic health records, imaging, biomarkers, and wearables, ML enhances patient stratification, refines inclusion criteria, and improves prediction of mortality, HF hospitalization, and treatment response. It also enables adaptive trial designs, continuous monitoring, and dynamic endpoint evaluation. Despite these advances, challenges related to bias, interpretability, and regulatory adaptation persist. ML complements rather than replacing conventional methodologies, and promotes more adaptive, inclusive, and patient-centered HF research. Responsible implementation—based on transparency, rigorous validation, and fairness—may redefine evidence generation and bridge clinical trials with real-world practice. ","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2026-03-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13032980/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147572857","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0